title: [Insulin analogues: modifications in the structure, molecular and metabolic consequences].
abstract: Recombinant DNA technology has provided insulin analogues for the treatment of diabetes mellitus, with an efficacy and safety that has improved the treatment of this disease. We briefly review the principal characteristics of the insulin analogues currently available. Both rapid-acting (lispro, aspart and glulisine) and long acting (glargine and determir) insulin analogues are included in this review. We describe the pharmacology of each insulin analogue, their differences with the human insulin, the administration, indication, efficacy and safety. In addition we discussed the main controversies of the use of these insulin analogues. In particular, those related with the risk of cancer and retinopathy, and their use in pregnant women.
authors.affiliation: Facultad de Medicina, Universidad de Valladolid, Valladolid, España. Dadluis@yahoo.es
authors.forename: D A
authors.initials: DA
authors.lastname: de Luis
authors.forename: E
authors.initials: E
authors.lastname: Romero
mesh_terms: D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D061268:Insulin Lispro / Q000627:therapeutic use; D015394:Molecular Structure; D013329:Structure-Activity Relationship
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro